1
|
Zhou N, Mitchell KG, Corsini EM, Truong VTT, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg 2021; 108:1207-1215. [PMID: 34095952 DOI: 10.1093/bjs/znab162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 04/14/2021] [Indexed: 11/14/2022]
Abstract
BACKGROUND Long-term survival outcomes of trimodal therapy (TMT; chemoradiation plus surgery) and bimodal therapy (BMT; chemoradiation) have seldom been analysed. In a selective-surgery paradigm, the benefit of TMT in patients with a complete clinical response is controversial. Factors associated with survival in patients with a clinical complete response to chemoradiation were evaluated. METHODS Patients with stage II-III oesophageal squamous cell carcinoma treated with TMT or BMT from 2002 to 2017 were evaluated. The BMT group consisted of patients who were otherwise eligible for surgery but underwent chemoradiation alone followed by observation. This group included patients who later had salvage oesophagectomy. Survival was evaluated and compared between TMT and BMT groups. Elastic net regularization was performed to select co-variables for Cox multivariable survival analysis in patients with a clinical complete response. RESULTS Of 143 patients, 60 (41.9 per cent) underwent TMT and 83 (58.0 per cent) BMT. Patients who underwent TMT had longer median overall survival than those who had BMT (77 versus 33 months; P = 0.019). For patients with a clinical complete response, TMT achieved longer median overall survival than BMT (123 versus 55 months; P = 0.04). BMT had a high locoregional recurrence rate (48 versus 6 per cent; P < 0.001); 26 of 29 patients with locoregional recurrence in the BMT groupunderwent salvage resection. Cox multivariable analysis demonstrated that upper-mid oesophageal tumour location (hazard ratio (HR) 2.04; P = 0.024) and tumour length (HR 1.18; P = 0.046) were associated with worse survival. Although TMT was not associated with survival, it was a predictor of reduced recurrence (HR 0.28; P = 0.028). The maximum standardized uptake value after chemoradiation also predicted recurrence (HR 1.33; P < 0.001). CONCLUSION In patients who achieve a clinical complete response, TMT reduces locoregional recurrence but may not prolong survival. The differences in survival outcomes may be due to patient selection; therefore, a selective-surgery strategy in oesophageal squamous cell carcinoma is a reasonable approach.
Collapse
Affiliation(s)
- N Zhou
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - K G Mitchell
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - E M Corsini
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - V T T Truong
- Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Texas, USA
| | - M B Antonoff
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - R J Mehran
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - R Rajaram
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - D C Rice
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J A Roth
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - B Sepesi
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - S G Swisher
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - A A Vaporciyan
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - G L Walsh
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J A Ajani
- Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - W L Hofstetter
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
2
|
Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus 2020; 33:5532833. [PMID: 31313820 DOI: 10.1093/dote/doz067] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 06/05/2019] [Accepted: 06/25/2019] [Indexed: 12/11/2022]
Abstract
The survival advantage associated with the addition of surgical therapy in esophageal squamous cell carcinoma (ESCC) patients who demonstrate a complete clinical response to chemoradiotherapy is unclear, and many institutions have adopted an organ-preserving strategy of selective surgery in this population. We sought to characterize our institutional experience of salvage esophagectomy (for failure of definitive bimodality therapy) and planned esophagectomy (as a component of trimodality therapy) by retrospectively analyzing patients with ESCC of the thoracic esophagus and GEJ who underwent esophagectomy following chemoradiotherapy between 2004 and 2016. Of 76 patients who met inclusion criteria, 46.1% (35) underwent salvage esophagectomy. Major postoperative complications (major cardiovascular and pulmonary events, anastomotic leak [grade ≥ 2], and 90-day mortality) were frequent and occurred in 52.6% of the cohort (planned resection: 36.6% [15/41]; salvage esophagectomy: 71.4% [25/35]). Observed rates of 30- and 90-day mortality for the entire cohort were 7.9% (planned: 7.3% [3/41]; salvage: 8.6% [3/35]) and 13.2% (planned: 9.8% [4/41]; salvage: 17.1% [6/35]), respectively. In summary, esophagectomy following chemoradiotherapy for ESCC at our institution has been associated with frequent postoperative morbidity and considerable rates of mortality in both planned and salvage settings. Although a selective approach to surgery may permit organ preservation in many patients with ESCC, these results highlight that salvage esophagectomy for failure of definitive-intent treatment of ESCC may also constitute a difficult clinical undertaking in some cases.
Collapse
Affiliation(s)
- K G Mitchell
- Department of Thoracic and Cardiovascular Surgery
| | - D B Nelson
- Department of Thoracic and Cardiovascular Surgery
| | - E M Corsini
- Department of Thoracic and Cardiovascular Surgery
| | | | - M B Antonoff
- Department of Thoracic and Cardiovascular Surgery
| | - R J Mehran
- Department of Thoracic and Cardiovascular Surgery
| | - D C Rice
- Department of Thoracic and Cardiovascular Surgery
| | - J A Roth
- Department of Thoracic and Cardiovascular Surgery
| | - B Sepesi
- Department of Thoracic and Cardiovascular Surgery
| | - G L Walsh
- Department of Thoracic and Cardiovascular Surgery
| | - M S Bhutani
- Department of Gastroenterology Hepatology and Nutrition
| | | | - C C Wu
- Department of Diagnostic Radiology
| | | | - J A Ajani
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - S G Swisher
- Department of Thoracic and Cardiovascular Surgery
| | | |
Collapse
|
3
|
Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer 2018; 108:17-24. [PMID: 30592991 DOI: 10.1016/j.ejca.2018.11.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 11/07/2018] [Accepted: 11/11/2018] [Indexed: 01/28/2023]
Abstract
BACKGROUND Akt activation is common in gastric/gastroesophageal junction cancer (GC/GEJC) and is associated with chemotherapy resistance. Treatment with ipatasertib, a pan-Akt inhibitor, may potentiate the efficacy of chemotherapy in GC/GEJC. PATIENTS AND METHODS In this randomised, double-blind, placebo-controlled, multicentre, phase II trial, patients with locally advanced or metastatic GC/GEJC not amenable to curative therapy were randomised 1:1 to receive ipatasertib or placebo, plus mFOLFOX6 (modified regimen of leucovorin, bolus and infusional 5-fluorouracil [5-FU], and oxaliplatin). The co-primary end-point was progression-free survival (PFS) in the intent-to-treat (ITT) population and in phosphatase and tensin homolog (PTEN)-low patients. Secondary end-points included PFS in patients with PI3K/Akt pathway-activated tumours; overall survival, investigator-assessed objective response rate and duration of response in the ITT population; and safety assessments. RESULTS In 153 enrolled patients, the median PFS (ITT) was 6.6 months (90% confidence interval [CI], 5.7-7.5) with ipatasertib/mFOLFOX6 versus 7.5 months (90% CI, 6.2-8.1) with placebo/mFOLFOX6 (hazard ratio, 1.12; 90% CI, 0.81-1.55; P = 0.56). No statistically significant PFS benefit was observed in biomarker-selected patient subgroups (PTEN-low and PI3K/Akt pathway-activated tumours) with ipatasertib/mFOLFOX6 versus placebo/mFOLFOX6. Other secondary end-points did not favour the ipatasertib/mFOLFOX6 treatment arm. The percentages of patients with ≥1 adverse event (AE, 100% versus 98%) and grade ≥3 AEs (79% versus 74%) were similar between arms. Higher rates of AEs leading to treatment withdrawal (16% versus 6%) and serious AEs were reported in the ipatasertib arm (54% versus 43%). Thirty-nine and 29 deaths occurred in the ipatasertib and placebo arms, respectively. CONCLUSIONS Ipatasertib/mFOLFOX6 compared with placebo/mFOLFOX6 did not improve PFS in unselected or biomarker-selected patients. No unexpected safety concerns were observed. TRIAL REGISTRATION ClinicalTrials.gov (NCT01896531).
Collapse
Affiliation(s)
- Y-J Bang
- Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu Seoul 03080, South Korea.
| | - Y-K Kang
- Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.
| | - M Ng
- National Cancer Centre Singapore, Singapore.
| | - H C Chung
- Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Yonsei-ro 50-1 Seodaemun-gyu Shinchon-dong 134 Seoul 03722, South Korea.
| | - Z A Wainberg
- David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
| | - S Gendreau
- Genentech, Inc., South San Francisco, CA 94080, USA.
| | - W Y Chan
- Genentech, Inc., South San Francisco, CA 94080, USA.
| | - N Xu
- Genentech, Inc., South San Francisco, CA 94080, USA.
| | - D Maslyar
- Genentech, Inc., South San Francisco, CA 94080, USA.
| | - R Meng
- Genentech, Inc., South San Francisco, CA 94080, USA.
| | - I Chau
- The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom SM2 5PT UK.
| | - J A Ajani
- Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| |
Collapse
|
4
|
Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus 2018; 31:4944973. [PMID: 29579257 DOI: 10.1093/dote/dox127] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Accepted: 09/19/2017] [Indexed: 12/11/2022]
Abstract
Weight loss after esophagectomy is common and is associated with unfavorable prognosis. However, the clinical features and surgical methods that influence postesophagectomy weight loss are not well characterized. This study aims to determine those features (especially the surgical methods) that may affect postoperative weight loss. We reviewed 221 esophageal cancer patients who had undergone esophagectomy at Kumamoto University Hospital (Kumamoto, Japan) between November 2012 and June 2015. Among these, we recruited 106 patients who had undergone transthoracic esophagectomy with gastric conduit reconstruction, had no cancer recurrence within 1 year, and no missing follow-up data. We tabulated the body weight changes and risk factors associated with weight loss exceeding 10% at 1-year postesophagectomy. The mean body weights at baseline and 1-year postsurgery were 60.3 kg (standard error (SE): 0.91) and 52.6 (SE: 0.91), respectively. One year postsurgery, the body weights had changed as follows: mean: -12.2%; median: -12.9%; standard deviation: 9.06; range: -36.1-18.56%; interquartile range: -10.5 to -14.0%. In the multivariate logistic regression analysis, the absence of pyloroplasty was the sole risk factor for more than 10% weight loss (OR: 3.22; 95% CI: 1.08-11.9; P = 0.036). Our data suggest that pyloroplasty with esophagectomy can overcome the post-surgical weight loss.
Collapse
Affiliation(s)
- K Harada
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto.,Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | - N Yoshida
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - Y Baba
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - K Nakamura
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - K Kosumi
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - T Ishimoto
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - M Iwatsuki
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - Y Miyamoto
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - Y Sakamoto
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| | - J A Ajani
- Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | - M Watanabe
- Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
| | - H Baba
- Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto
| |
Collapse
|
5
|
Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol 2017; 28:2077-2085. [PMID: 28430862 DOI: 10.1093/annonc/mdx191] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Traditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical studies has been studied using overall survival and more recently tumor-based end points such as progression-free survival, measurements of response to treatment. However, these seem not to be the relevant clinical end points in current situation if such end points were no validated as surrogate of overall survival to demonstrate the clinical efficacy. Appropriate, meaningful, primary patient-oriented and patient-reported end points that adequately measure the effects of new therapeutic interventions are then crucial for the advancement of clinical research in metastatic colorectal cancer to complement the results of tumor-based end points. Health-related quality of life (HRQoL) is effectively an evaluation of quality of life and its relationship with health over time. HRQoL includes the patient report at least of the way a disease or its treatment affects its physical, emotional and social well-being. Over the past few years, several phase III trials in a variety of solid cancers have assessed the incremental value of HRQoL in addition to the traditional end points of tumor response and survival results. HRQoL could provide not only complementary clinical data to the primary outcomes, but also more precise predictive and prognostic value. This end point is useful for both clinicians and patients in order to achieve the dogma of precision medicine. The present article examines the use of HRQoL in phase III metastatic colorectal cancer clinical trials, outlines the importance of HRQoL assessment methods, analysis, and results presentation. Moreover, it discusses the relevance of including HRQoL as a primary/co-primary end point to support the progression-free survival results and to assess efficacy of treatment in the advanced disease setting.
Collapse
Affiliation(s)
- F Bonnetain
- Methodology and Quality of Life Unit, Oncology Department (INSERM UMR 1098), Quality of Life and Cancer Clinical Research Platform
| | - C Borg
- Department of Medical Oncology, University Hospital of Besançon, Besançon
- Centre d'Investigation Clinique en Biothérapie, CIC-1431, Nantes
- 11UMR1098 INSERM/Université de Franche Comté/Etablissement Français du Sang, Besançon
- Department of Oncology, University Hospital of Besançon, Besançon, France
| | - R R Adams
- Cardiff University and Velindre Cancer Centre, Cardiff, UK
| | - J A Ajani
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - A Benson
- Division of Hematology/Oncology, Northwestern Medical Group, Chicago, USA
| | - H Bleiberg
- Montagne de Saint Job, Brussels, Belgium
| | - B Chibaudel
- Institut Hospitalier Franco-Britannique, Levallois-Perret, France
| | - E Diaz-Rubio
- Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - J Y Douillard
- Medical Oncology, Institut de Cancérologie de l'Ouest (ICO), Nantes St-Herblain, France
| | - C S Fuchs
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - B J Giantonio
- Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia
| | - R Goldberg
- Department of Medicine, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, USA
| | - V Heinemann
- Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - M Koopman
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - R Labianca
- Cancer Center, Ospedale Giovanni XXIII, Bergamo, Italy
| | - A K Larsen
- Cancer Biology and Therapeutics, INSERM and Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France
| | - T Maughan
- CRUK/MRC Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Oxford, UK
| | - E Mitchell
- Department of Medical Oncology, Thomas Jefferson University, Philadelphia, USA
| | - M Peeters
- Department of Oncology, Center for Oncological Research Antwerp, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
| | - C J A Punt
- Department of Medical Oncology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - H J Schmoll
- Department of Internal Medicine IV, University Clinic Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - C Tournigand
- Department of Oncology, University of Paris Est Creteil; APHP, Henri-Mondor Hospital, Créteil, France
| | - A de Gramont
- Institut Hospitalier Franco-Britannique, Levallois-Perret, France
| |
Collapse
|
6
|
Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol 2013; 8:142-9. [PMID: 24210755 DOI: 10.1016/j.molonc.2013.10.007] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 10/14/2013] [Accepted: 10/15/2013] [Indexed: 01/16/2023] Open
Abstract
PURPOSE Operable thoracic esophageal/gastroesophageal junction carcinoma (EC) is often treated with chemoradiation and surgery but tumor responses are unpredictable and heterogeneous. We hypothesized that aldehyde dehydrogenase-1 (ALDH-1) could be associated with response. METHODS The labeling indices (LIs) of ALDH-1 by immunohistochemistry in untreated tumor specimens were established in EC patients who had chemoradiation and surgery. Univariate logistic regression and 3-fold cross validation were carried out for the training (67% of patients) and validation (33%) sets. Non-clinical experiments in EC cells were performed to generate complimentary data. RESULTS Of 167 EC patients analyzed, 40 (24%) had a pathologic complete response (pathCR) and 27 (16%) had an extremely resistant (exCRTR) cancer. The median ALDH-1 LI was 0.2 (range, 0.01-0.85). There was a significant association between pathCR and low ALDH-1 LI (p ≤ 0.001; odds-ratio [OR] = 0.432). The 3-fold cross validation led to a concordance index (C-index) of 0.798 for the fitted model. There was a significant association between exCRTR and high ALDH-1 LI (p ≤ 0.001; OR = 3.782). The 3-fold cross validation led to the C-index of 0.960 for the fitted model. In several cell lines, higher ALDH-1 LIs correlated with resistant/aggressive phenotype. Cells with induced chemotherapy resistance upregulated ALDH-1 and resistance conferring genes (SOX9 and YAP1). Sorted ALDH-1+ cells were more resistant and had an aggressive phenotype in tumor spheres than ALDH-1- cells. CONCLUSIONS Our clinical and non-clinical data demonstrate that ALDH-1 LIs are predictive of response to therapy and further research could lead to individualized therapeutic strategies and novel therapeutic targets for EC patients.
Collapse
Affiliation(s)
- J A Ajani
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA.
| | - X Wang
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - S Song
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - A Suzuki
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - T Taketa
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - K Sudo
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R Wadhwa
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - W L Hofstetter
- Department of Cardiac and Thoracic Surgery, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R Komaki
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - D M Maru
- Department of Pathology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - J H Lee
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - M S Bhutani
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - B Weston
- Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - V Baladandayuthapani
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - Y Yao
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - S Honjo
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - A W Scott
- Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - H D Skinner
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - R L Johnson
- Department of Genetics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| | - D Berry
- Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA
| |
Collapse
|
7
|
Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol 2013; 24:2854-9. [PMID: 23994746 DOI: 10.1093/annonc/mdt340] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Patients with localized esophageal adenocarcinoma (EAC) who achieve a clinical complete response (clinCR) after preoperative chemoradiation (trimodality therapy; TMT) or definitive chemoradiation (bimodality therapy; BMT) live longer than those who achieve a <clinCR (Suzuki A, Xiao LC, Hayashi Y et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011; 117: 4823-4833; Cheedella NK, Suzuki A, Xiao L et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 2013; 24: 1262-1266; Ajani JA, Correa AM, Hofstetter WL et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23: 2638-2642). We hypothesized that the initial standardized uptake value (iSUV) of positron emission tomography will define novel subsets of clinCR patients. METHODS We analyzed 323 EAC patients, from our prospective database, who achieved a clinCR. Various statistical methods were used to assess the influence of iSUV on patient outcome. RESULTS The median follow-up of 323 patients was 40.8 months [95% confidence interval (CI) 35.6-47.3 months]. Two hundred six (63.8%) patients had TMT and 117 (36.2%) had BMT. If iSUV was ≥6, TMT patients had a longer median OS (94.8 months; 95% CI 66.07-NA) than BMT patients (31.4 months; 95% CI 21.7-42.1; P ≤ 0.001). However, if iSUV was <6, the median OS of TMT and BMT patients was similar (P = 0.62). iSVU did not influence the pathologic complete response rate in TMT patients (P = 0.85). CONCLUSION clinCR patients with iSUV of <6 are identified as a new subset that fared equally well when treated with TMT or BMT. Future esophageal preservation strategy may be best suited for this newly identified subset of EAC patients.
Collapse
Affiliation(s)
- A Suzuki
- Department of Gastrointestinal Medical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2013; 24:2844-9. [PMID: 23975663 DOI: 10.1093/annonc/mdt339] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would increase the rate of pathologic complete response (pathCR). METHODS Trimodality-eligibile patients were randomized to receive no IC (Arm A) or IC (oxaliplatin/FU; Arm B) before oxaliplatin/FU/radiation. Surgery was attempted ∼5-6 weeks after chemoradiation. The pathCR rate, post-surgery 30-day mortality, overall survival (OS), and toxic effects were assessed. Bayesian methods and Fisher's exact test were used. RESULTS One hundred twenty-six patients were randomized dynamically to balance the two arms for histology, baseline stage, gender, race, and age. Fifty-five patients in Arm A and 54 in Arm B underwent surgery. The median actuarial OS for all patients (54 deaths) was 45.62 months [95% confidence interval (CI), 27.63-NA], with median OS 45.62 months (95% CI 25.56-NA) in Arm A and 43.68 months (95% CI 27.63-NA) in Arm B (P = 0.69). The pathCR rate in Arm A was 13% (7 of 55) and 26% (14 of 54) in Arm B (two-sided Fisher's exact test, P = 0.094). Safety was similar in both arms. CONCLUSIONS These data suggest that IC produces non-significant increase in the pathCR rate and does not prolong OS. Further development of IC before chemoradiation may not be beneficial. Clinical trial no.: NCT 00525915 (www.clinicaltrials.gov).
Collapse
Affiliation(s)
- J A Ajani
- Departments of Gastrointestinal Medical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013; 49:3616-24. [PMID: 23899532 DOI: 10.1016/j.ejca.2013.07.003] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Accepted: 07/01/2013] [Indexed: 12/16/2022]
Abstract
BACKGROUND The aim of developing oral fluorouracil (5-FU) is to provide a more convenient administration route with similar efficacy and the best achievable tolerance. S-1, a novel oral fluoropyrimidine, was specifically designed to overcome the limitations of intravenous fluoropyrimidine therapies. PATIENTS AND METHODS A multicentre, randomised phase 3 trial was undertaken to compare S-1/cisplatin (CS) with infusional 5-FU/cisplatin (CF) in 1053 patients with untreated, advanced gastric/gastroesophageal adenocarcinoma. This report discusses a post-hoc noninferiority overall survival (OS) and safety analyses. RESULTS Results (1029 treated; CS = 521/CF = 508) revealed OS in CS (8.6 months) was statistically noninferior to CF (7.9 months) [hazard ratio (HR) = 0.92 (two-sided 95% confidence interval (CI), 0.80-1.05)] for any margin equal to or greater than 1.05. Statistically significant safety advantages for the CS arm were observed [G3/4 neutropenia (CS, 18.6%; CF, 40.0%), febrile neutropenia (CS, 1.7%; CF, 6.9%), G3/4 stomatitis (CS, 1.3%; CF, 13.6%), diarrhoea (all grades: CS, 29.2%; CF, 38.4%) and renal adverse events (all grades: CS, 18.8%; CF, 33.5%)]. Hand-foot syndrome, infrequently reported, was mainly grade 1/2 in both arms. Treatment-related deaths were significantly lower in the CS arm than the CF arm (2.5% and 4.9%, respectively; P<0.047). CONCLUSION CS is noninferior to CF with a better safety profile and provides a new treatment option for patients with advanced gastric carcinoma.
Collapse
Affiliation(s)
- J A Ajani
- Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus 2013; 26:708-15. [PMID: 23350713 DOI: 10.1111/dote.12019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Trimodality therapy with neoadjuvant chemoradiation followed by surgery significantly improves the survival of locally advanced (clinical stage IIA-III) esophageal cancer patients compared to treatment with surgery alone. This has resulted in an increased use of neoadjuvant therapy in recent years, yet little is known regarding how this increase has impacted the utilization of surgery in the treatment of locally advanced disease. Although previous reports of experimental protocols suggest that 90-95% of patients complete trimodality therapy including a surgical resection, trimodality therapy completion among adenocarcinoma patients eligible for curative resection has not been evaluated in a nonprotocol setting. We sought to (i) assess the completion of trimodality therapy among locally advanced esophageal adenocarcinoma patients; (ii) characterize the reasons for avoiding surgery; and (iii) identify factors associated with failure to complete trimodality therapy. We identified 296 patients with locally advanced esophageal adenocarcinoma eligible for trimodality therapy at our institution. All patients were evaluated in a multidisciplinary setting and considered eligible for curative resection after initial staging and physiologic assessment. Multivariable logistic regression was used to identify factors associated with failure to complete trimodality therapy. Of 296 trimodality-eligible patients, 33% (97/296) did not complete trimodality therapy. Reasons for not undergoing surgery included patient choice (27.8%, 27/97), distant progression of disease during chemoradiation (23.7%, 23/97), and physician preference for surveillance (23.7%, 23/97). In addition, 17.5% (17/97) of patients had physical deterioration in performance status, and treatment-related deaths occurred in 7.2% (7/97) prior to surgery. In the total study population (n = 296), multivariable logistic regression identified older age (≥70 years: odds ratio [OR] = 6.611, 95% confidence interval [CI]: 2.900-15.071), pretreatment standard uptake value (6.8-10.1: OR = 2.393, 95% CI: 1.050-5.455; ≥15.8: OR = 3.623, 95% CI: 1.604-8.186), and a radiation dose of 50.4 Gy (OR = 5.312, 95% CI: 2.365-11.929) as being significantly associated with failure to complete trimodality therapy. Among the subgroup of patients that successfully completed chemoradiation (n = 266), older patients (≥70 years: OR = 9.606, 95% CI: 3.637-25.372), those with a comorbidity score of 2 or higher (OR = 4.059, 95% CI: 1.257-13.103), and those that received a radiation dose of 50.4 Gy (OR = 4.878, 95% CI: 1.974-12.054) were at a significantly higher risk of not completing trimodality therapy. Trimodality therapy completion among patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting is considerably lower than what has previously been reported in clinical trials. Our findings suggest that a selective approach to surgery is commonly utilized in clinical practice. Trimodality-eligible patients that are older and have a higher comorbidity score are at risk for not completing trimodality therapy.
Collapse
Affiliation(s)
- C C Murphy
- Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center; University of Texas School of Public Health, Houston, Texas, USA
| | | | | | | | | | | |
Collapse
|
11
|
Cheedella NKS, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 2012; 24:1262-6. [PMID: 23247658 DOI: 10.1093/annonc/mds617] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Chemoradiation followed by surgery is the preferred treatment of localized gastroesophageal cancer (GEC). Surgery causes considerable life-altering consequences and achievement of clinical complete response (clinCR; defined as postchemoradiation [but presurgery] endoscopic biopsy negative for cancer and positron emission tomographic (PET) scan showing physiologic uptake) is an enticement to avoid/delay surgery. We examined the association between clinCR and pathologic complete response (pathCR). PATIENTS AND METHODS Two hundred eighty-four patients with GEC underwent chemoradiation and esophagectomy. The chi-square test, Fisher exact test, t-test, Kaplan-Meier method, and log-rank test were used. RESULTS Of 284 patients, 218 (77%) achieved clinCR. However, only 67 (31%) of the 218 achieved pathCR. The sensitivity of clinCR for pathCR was 97.1% (67/69), but the specificity was low (29.8%; 64/215). Of the 66 patients who had less than a clinCR, only 2 (3%) had a pathCR. Thus, the rate of pathCR was significantly different in patients with clinCR than in those with less than a clinCR (P < 0.001). CONCLUSIONS clinCR is not highly associated with pathCR; the specificity of clinCR for pathCR is too low to be used for clinical decision making on delaying/avoiding surgery. Surgery-eligible GEC patients should be encouraged to undergo surgery following chemoradiation despite achieving a clinCR.
Collapse
Affiliation(s)
- N K S Cheedella
- Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23:2638-2642. [PMID: 22831985 DOI: 10.1093/annonc/mds210] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Approximately 25% of patients with esophageal cancer (EC) who undergo preoperative chemoradiation, achieve a pathologic complete response (pathCR). We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability. PATIENTS AND METHODS We analyzed 322 patients with EC who underwent preoperative chemoradiation. All the patients had baseline and postchemoradiation positron emission tomography (PET) and pre- and postchemoradiation endoscopic biopsy. Logistic regression models were used for analysis, and cross-validation via the bootstrap method was carried out to test the model. RESULTS The 70 (21.7%) patients who achieved a pathCR lived longer (median overall survival [OS], 79.76 months) than the 252 patients who did not achieve a pathCR (median OS, 39.73 months; OS, P = 0.004; disease-free survival, P = 0.003). In a logistic regression analysis, the following parameters contributed to the prediction model: postchemoradiation PET, postchemoradiation biopsy, sex, histologic tumor grade, and baseline (EUS)T stage. The area under the receiver-operating characteristic curve was 0.72 (95% confidence interval [CI] 0.662-0.787); after the bootstrap validation with 200 repetitions, the bias-corrected AU-ROC was 0.70 (95% CI 0.643-0.728). CONCLUSION Our data suggest that the logistic regression model can predict pathCR with a high probability. This clinical model could complement others (biomarkers) to predict pathCR.
Collapse
Affiliation(s)
- J A Ajani
- Departments of Gastrointestinal Medical Oncology, Houston, USA.
| | - A M Correa
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - W L Hofstetter
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - D C Rice
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - M A Blum
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - A Suzuki
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - T Taketa
- Departments of Gastrointestinal Medical Oncology, Houston, USA
| | - J Welsh
- Departments of Radiation Oncology, Houston, USA
| | - S H Lin
- Departments of Radiation Oncology, Houston, USA
| | - J H Lee
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - M S Bhutani
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - W A Ross
- Departments of Gastroenterology, Hepatology, and Nutrition, Houston, USA
| | - D M Maru
- Departments of Pathology, Houston, USA
| | | | - J Erasmus
- Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R Komaki
- Departments of Radiation Oncology, Houston, USA
| | - R J Mehran
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - A A Vaporciyan
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| | - S G Swisher
- Departments of Thoracic and Cardiovascular Surgery, Houston, USA
| |
Collapse
|
13
|
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 2011; 25:614-22. [PMID: 22150920 DOI: 10.1111/j.1442-2050.2011.01290.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
High body mass index (H-BMI; ≥25 kg/m(2) ) is common in US adults. In a small cohort of esophageal cancer (EC) patients treated with surgery, H-BMI and diagnosis of early stage EC appeared associated. We evaluated a much larger cohort of EC patients. From a prospectively maintained database, we analyzed 925 EC patients who had surgery with or without adjunctive therapy. Various statistical methods were used. Among 925 patients, 69% had H-BMI, and 31% had normal body mass index (<25 kg/m(2) ; N-BMI). H-BMI was associated with men (P<0.001), Caucasians (P=0.064; trend), lower esophageal localization (P<0.001), adenocarcinoma histology (P<0.001), low baseline cT-stage (P=0.003), low baseline overall clinical stage (P=0.003), coronary artery disease (P=0.036), and diabetes (P<0.001). N-BMI was associated with weight loss (P<0.001), alcohol abuse (P=0.056; trend), ever/current smoking (P=0.014), and baseline cN+ (P=0.018). H-BMI patients with cT1 tumors (n=110) had significantly higher rates of gastresophageal reflux disease symptoms (P<0.001), gastresophageal reflux disease history (P<0.001), and Barrett's esophagus history (P<0.001) compared with H-BMI patients with cT2 tumors (n=114). Median survival of N-BMI patients was 36.66 months compared with 53.20 months for H-BMI patients (P=0.005). In multivariate analysis, older age (P<0.001), squamous histology (P=0.002), smoking (P=0.040), weight loss (P=0.002), high baseline stage (P<0.001), high number of ypN+ (P=0.005), high surgical stage (P<0.001), and American Society of Anesthesia scores, three out of four (P<0.001) were independent prognosticators for poor overall survival. We were able to perform propensity-based analysis of surgical complications between H-BMI and N-BMI patients. A comparison of fully matched 376 patients (188 with H-BMI and 188 with N-BMI) found no significant differences in the rate of complications between the two groups. This larger data set confirms that a fraction of H-BMI patients with antecedent history is diagnosed with early baseline EC. Upon validation of our data in an independent cohort, refinements in surveillance of symptomatic H-BMI patients are warranted and could be implemented. Our data also suggest that H-BMI patients do not experience higher rate of surgical complications compared with N-BMI patients.
Collapse
Affiliation(s)
- Y Hayashi
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Suzuki A, Lee JH, Bhutani MS, Lin SH, Welsh J, Maru D, Swisher S, Ajani JA. The association between body mass index and baseline clinical stage of esophageal carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Baker JS, Qureshi A, Itri L, Sun W, Mulcahy MF, Ajani JA. Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Suzuki A, Xiao L, Hayashi Y, Welsh J, Lin SH, Maru D, Hofstetter WL, Mehran RJ, Lee JH, Bhutani MS, Macapinlac HA, Liao ZX, Ajani JA. Prognostic significance of post-treatment standardized uptake value (pSUV) of positron emission tomography (PET) to predict overall survival (OS) and relapse-free survival (RFS) in patients with esophageal or gastroesophageal cancer treated with definitive chemoradiotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Tan IB, Grabsch H, Toh HC, Lee J, Boussioutas A, Rha SY, Ajani JA, Tan P. Comparing the classification precision and prognostic performance of an intrinsic gastric cancer signature with existing genomic signatures in six independent datasets. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Alsina M, Ko AH, Garcia De Paredes M, Rivera F, Schwartzberg LS, Fattaey A, Kunkel LA, Tabernero J, Ajani JA. Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4122] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Ajani JA, Wang X, Hayashi Y, Maru D, Welsh J, Hofstetter WL, Lee JH, Bhutani MS, Suzuki A, Berry DA, Izzo J. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Bhosale P, Ajani JA, Baker JS, Whiteside M, Castillo J, Kunkel LA. Onset of CT scan morphological changes in metastatic lesions and associated responses in gastric patients treated with telatinib. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
81 Background: Response to the antiangiogenic agent, bevacizumab, by CT has been associated with a unique morphologic change in liver metastasis (mets) where heterogeneous attenuation, variable degree of enhancement and ill-defined borders before treatment transform into homogeneous, hypoattenuating lesions with well defined borders, mimicking a cyst. CT-based morphologic criteria in colorectal cancer (CRC) had a statistically significant association with pathologic response and overall survival, (Chun, JAMA 2009). The CT changes likely reflect the replacement of mets by fibroconnective tissue rather than tumor necrosis. Telatinib (tel) is a novel orally available kinase inhibitor that is highly selective for the VEGFR, PDGFR, and KIT tyrosine kinases at nanomolar concentrations with potent antiangiogenic activity. Methods: TEL0805, a Phase 2 study administered tel with capecitabine (X) and cisplatin (P) in previously untreated metastatic or unresectable gastric or GEJ adenocarcinoma pts. Response assessments were every 2 cycles (6 weeks). The ORR in response evaluable pts was 69% (1 CR, 21 PR in 32 pts). CT films from 16/32 response evaluable pts were analyzed and reviewed by a radiologist at a single institution, 10 pts had liver mets. Results: The median onset of response was 49 days. CT changes of mets at week 6 scans included: decreased attenuation and/or a sharp interface with rapid reduction of mets (n=6); mixed response, with decreased attenuation but persistent borders, and/or slight increase in mets followed by onset of response week 12 (n=3), and PD (n=1). CT changes correlate with durable responses. Conclusions: Telatinib + XP produces rapid onset of tumor response with morphologic CT changes in gastric cancer liver mets similar to those observed in CRC pts with bevacizumab, consistent with antiangiogenic activity. Further analyses in a randomized setting to correlate CT morphologic response with survival are planned. [Table: see text]
Collapse
Affiliation(s)
- P. Bhosale
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| | - J. A. Ajani
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| | - J. S. Baker
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| | - M. Whiteside
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| | - J. Castillo
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| | - L. A. Kunkel
- University of Texas M. D. Anderson Cancer Center, Houston, TX; ACT Biotech, Inc., San Francisco, CA
| |
Collapse
|
22
|
Burd A, Castillo J, Whiteside M, White M, Ajani JA, Fattaey A, Kunkel LA. Pharmacokinetic and pharmacodynamic analysis of gastric cancer patients treated with telatinib. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
113 Background: The soluble form of the VEGFR2 receptor (sVEGFR2) neutralizes circulating VEGF, and functions as a negative feedback mechanism to enable partial inhibition of VEGF-stimulated endothelial cell migration and proliferation. In response to inhibition of VEGFR2 tyrosine kinase activity, up-regulation of VEGF expression and down-regulation of sVEGFR2 expression levels have been observed (Murukesh et al., 2010). Telatinib (tel) is a novel orally available kinase inhibitor that is highly selective for the VEGFR, PDGFR, and KIT tyrosine kinases at nanomolar concentrations with potent antiangiogenic activity. Correlation between telatinib exposure and reduction in plasma sVEGFR2 levels from baseline has previously been demonstrated in patient serum samples in phase I studies. Methods: TEL0805, a phase II study administered tel with capecitabine (X) and cisplatin (P) in previously untreated metastatic or unresectable gastric or GEJ adenocarcinoma pts. Patient serum samples were obtained on day -7, [6 plasma samples (pre-dose, and at 30 min, 1, 2, 3 and 4 hours)] and on day 1, [4 plasma samples (pre-dose and at 1, 2 and 3 hours)] and evaluated for the levels of telatinib and its M2 metabolite (M2). Additional serum samples were collected every 42 days and evaluated for VEGF and sVEGFR2 levels. Results: Measurement of tel and M2 levels confirmed previous pharmacokinetic findings and demonstrated no drug accumulation following continuous daily dosing. Baseline plasma sVEGFR2 levels have previously not been reported for advanced gastric cancer patients and displayed a wide range at disease presentation. Reduction in sVEGFR2 levels were noted for nearly all treated patients and correlated with the duration of stay on tel therapy. Conclusions: Telatinib continuous dosing is possible in combination with XP with little effect on tel exposure or accumulation. Reduction in sVEGFR2 levels may be useful in identifying patients who may benefit from tel treatment in this combination setting. [Table: see text]
Collapse
Affiliation(s)
- A. Burd
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. Castillo
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. Whiteside
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. White
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. A. Ajani
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. Fattaey
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - L. A. Kunkel
- ACT Biotech, Inc., San Francisco, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
23
|
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.367] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
367 Background: On initial publication of GI Intergroup RTOG 98-11, concurrent chemoradiation with 5FU+mitomycin (MMC) decreased colostomy failure (CF) vs induction plus concurrent 5FU+cisplatin (CDDP), but did not significantly impact disease free or overall survival (DFS, OS). The intent of the current analysis is to determine the long-term impact of treatment on survival (DFS, OS, colostomy-free [CFS]), CF and relapse (local-regional [LRF], distant [DM]) in this patient group. Methods: Stratification factors included gender, clinical node status, and primary size. DFS/OS were estimated univariately by Kaplan-Meier method and treatment arms compared by log-rank test. Time to relapse/CF were estimated by cumulative incidence method and treatment arms compared by Gray's test. Multivariate analyses were done with Cox proportional hazard models to test for treatment differences, adjusting for stratification factors. Results: Of 682 patients accrued, 649 were analyzable for outcomes. As seen in the table, 5-yr DFS and OS were statistically better for RT+5FU/MMC vs RT+5FU/CDDP (67.7 v 57.6%, p=.0.0045; 78.2 v 70.5%, p=0.021) with trends toward statistical significance for CFS, LRF, and CF (71.8 v 64.9%, p=0.053; 20 v 26.5%, 11.9 v 17.3%, p=0.092 and 0.075). Similar results were seen in multivariate analysis. Conclusions: Concurrent chemoradiation with 5FU-MMC has a statistically significant impact on DFS and OS vs induction + concurrent 5FU-CDDP and borderline significance for CFS, CF and LRF. Therefore, RT+5FU/MMC remains the preferred standard of care. Potential strategies to improve outcomes include treatment intensification and individualized molecular-based treatment. Supported by RTOG grant U10 CA21661 and CCOP grant U10 CA37422 from the National Cancer Institute (NCI). [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. L. Gunderson
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - K. A. Winter
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - J. A. Ajani
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - J. E. Pedersen
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - A. B. Benson
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - C. R. Thomas
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - R. J. Mayer
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - M. G. Haddock
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - T. A. Rich
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| | - C. G. Willett
- Mayo Clinic Cancer Center Arizona, Scottsdale, AZ; RTOG Statistical Center, Philadelphia, PA; University of Texas M. D. Anderson Cancer Center, Houston, TX; Cross Cancer Institute, Edmonton, AB, Canada; Northwestern University Feinberg School of Medicine, Chicago, IL; Knight Cancer Institute/Oregon Health & Science University, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Virginia Medical Center, Charlottesville, VA; Duke University Medical Center,
| |
Collapse
|
24
|
Suzuki A, Xiao L, Hayashi Y, Welsh J, Lin SH, Lee JH, Bhutani MS, Hofstetter WL, Mehran RJ, Ajani JA. Value of the primary tumor initial standardized uptake value (iSUV) of 18F-fluorodeoxyglucose positron emission tomography (PET) to predict overall survival (OS) in patients with esophageal or gastroesophageal junction carcinoma undergoing definitive chemoradiotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
82 Background: The value of iSUV of PET for predicting OS is unclear in patients with advanced esophageal or gastroesophageal carcinoma treated with definitive chemoradiotherapy. We tested the hypothesis that iSUV would correlate with OS and recurrence free survival (RFS). Methods: We performed retrospective analysis, selecting patients with esophageal or gastroesophageal carcinoma who had a pretreatment PET and endoscopic ultrasonography (EUS) and who received definitive chemoradiotherapy from 2002 to 2008. Correlations were performed with continuous and dichotomized iSUV, baseline EUS results, OS, and RFS. Results: Two hundred and nine patients were analyzed. The median OS time was 20.7 months (95% CI: 18.8-26.3 months) and the median RFS time was 11.2 months (95% CI: 9.44, 14.34). OS rate and RFS rate at 3 years were 35.7% (95% CI: 29.0-43.9%) and 24.8% (95 % CI: 19.1–32.1 %). The median iSUV was 12.7 (range: 0–51). In univariate analysis, iSUV was associated with OS (Cox model, P = 0.012; log-rank test, P = 0.002) and RFS (Cox model, P = 0.0003; log-rank test, P < 0.0001). In multivariate analysis, dichotomized iSUV cut off by median was associated with OS (P = 0.024) but not RFS (P = 0.11). Conclusions: Data from our study suggests that higher iSUV is associated with poor survival. Baseline PET may become a useful stratification factor in randomized trials and for individualized therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Suzuki
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - L. Xiao
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - Y. Hayashi
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. Welsh
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - S. H. Lin
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. H. Lee
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. S. Bhutani
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - R. J. Mehran
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. A. Ajani
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
25
|
Yoshida K, Ikeda K, Yoshisue K, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Saito K, Benedetti FM, Ajani JA. Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.53] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
53 Background: This analysis was performed to establish the PPK model of S-1, and to identify the intrinsic or extrinsic factors that influence S-1 exposure in the Western patients with advanced solid tumor. Methods: PK data obtained in seven phase I and one phase III (FLAGS) studies were combined for PPK analysis. The total number of patients was 315, and the number of data points for FT, CDHP, 5-FU and Oxo were 2,860, 2,625, 2,492, and 2,484, respectively. The two-compartment model was used for FT, CDHP and Oxo, whereas for 5-FU, inhibitory effect of CDHP on 5-FU clearance was incorporated into a two-compartment model to describe its non-linear PK. The final models were validated by visual predictive check and bootstrapping. Results: The individual fit and the stability of four models were acceptable. The predicted daily AUCs (at steady state) were calculated to evaluate the effect of covariates. The daily AUC of 5-FU strongly correlated with oral clearance (CL/F) of CDHP, but not with that of FT. The ethnic difference in exposure to 5-FU was not apparent despite the significantly lower CL/F of FT observed in the Asian patients. Co-administration with food delayed the absorption of S-1 but exhibited no or limited effect on the AUC of FT, CDHP and 5-FU, whereas the bioavailability of Oxo decreased to approximately 30%. Renal function primarily influenced CDHP exposure and, in turn, 5-FU. The model simulation suggested that the S-1 dosages of 30, 25 and 20 mg/m2 BID could achieve similar daily AUC of 5-FU in the Western patients with normal renal function (CLcr>80 mL/min), mild (50-80 mL/min) and moderate (30-50 mL/min) renal impairment, respectively. Other factors such as age, gender, liver function, serum albumin, PS, gastric cancer, gastrectomy, combination with cisplatin and liver metastasis, had little or minimal impact on the daily AUC of 5-FU. Conclusions: This analysis suggests that the daily AUC of 5-FU after S-1 administration is primarily affected by the CDHP levels, and hence renal function remains the primary factor for 5-FU PK in patients. Other factors as well as CL/F of FT had little impact on 5-FU. [Table: see text]
Collapse
Affiliation(s)
- K. Yoshida
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Ikeda
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Yoshisue
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - W. Rodriguez
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - G. Bodoky
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - V. Moiseyenko
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. Lichinitser
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Saito
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - F. M. Benedetti
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. A. Ajani
- Taiho Pharmaceutical, Tokushima, Japan; Clinica Ricardo Palma and INEN, Lima, Peru; Fovarosi Onkormanyzat Egyesitett Szent Imre es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Taiho Pharmaceutical, Tokyo, Japan; Taiho Pharmaceutical, Princeton, NJ; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
26
|
Ko AH, Tabernero J, Garcia De Paredes M, Rivera F, Schnell FM, Baker JS, Phan AT, Alsina M, Patel K, Ajani JA. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14575] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Swisher S, Ajani JA. The influence of pretreatment body mass index on long-term prognosis of patients with esophageal carcinoma after surgery. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Ajani JA. Reply to D. Vordermark. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.22.0011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
29
|
Ajani JA, Rodriquez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4511] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4511 Background: The primary analysis of FLAGS (ASCO-GI-2009) showed that CS and CF had similar overall survival (OS) but CS had a significantly superior safety profile. Methods: 1,053 (1,029 treated; CS=521/CF=508) patients with untreated, advanced gastric/gastroesophageal adenocarcinoma were randomized to either S-1 (25 mg/m2 bid, d 1–21)/cisplatin (75 mg/m2 d 1) q 28 d or 5-FU (1,000 mg/m2/d 5-d infusion)/cisplatin (100 mg/m2 d 1) q 28 d. OS analyses for non-inferiority (NI), by pre-specified stratifications, and by the largest histologic subset (diffuse type histology) were performed. Results: OS for NI: OS from CS compared to CF had a HR=0.92 (two-sided 95% CI, 0.80–1.05). HR=1.05 being much lower than HR=1.22 derived from the literature. Using a stringent HR non-inferiority margin of 1.10, CS remains statistically significantly non-inferior (p=0.0068) to CF. The 74% preserved control effect by CS is well above the suggested 50% by Rothmann et al. (Statist-Med2003;22:239–264). OS by stratifications: Of 12 stratification sub-categories, CS produced OS HR=<1.0 in 9 and HR=>1.0 in 3. Subset analysis: OS analysis for diffuse type histology (n=590) showed that CS (median survival=9.0 months) resulted in a superior OS (Log rank p=0.0413; HR, 0.83 [95% CI, 0.70 to 0.99]) than CF (median survival=7.1 months). Conclusions: CS is statistically non-inferior to CF while proving much safer for the patients. CS resulted in a HR=<1.0 in the majority of pre-specified stratifications and CS produced statistically superior OS for patients with diffuse type histology (needs prospective studies). CS is an optimum substitute for CF. Supported by Taiho Pharma, USA. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Ajani
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - W. Rodriquez
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - G. Bodoky
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - V. Moiseyenko
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - M. Lichinitser
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - V. Gorbunova
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - I. Vynnychenko
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - A. Garin
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - I. Lang
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| | - S. Falcon
- M. D. Anderson Cancer Center, Houston, TX; Instituto de Oncologia y Radioterapia, Lima, Peru; Onkologiai Osztaly, Budapest, Hungary; N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Russian Cancer Research Center, Moscow, Russian Federation; Sumy Regional Oncology Centre, Sumy, Ukraine; Orszagos Onkologiai Intezet, Budapest, Hungary; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
| |
Collapse
|
30
|
Cen P, Correa AM, Lee JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus 2008; 22:32-41. [PMID: 19021684 DOI: 10.1111/j.1442-2050.2008.00881.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
It remains unclear whether the overall survival (OS) of patients with localized esophageal adenocarcinoma (LEA) with Barrett's esophagus (BE) (Barrett's-positive) and those with LEA without BE (Barrett's-negative) following preoperative chemoradiation is different. Based on the published differences in the molecular biology of the two entities, we hypothesized that the two groups will have a different clinical biology (and OS). In this retrospective analysis, all patients with LEA had surgery following preoperative chemoradiation. Apart from age, gender, baseline clinical stage, location, class of cytotoxics, post-therapy stage, and OS, LEAs were divided up into Barrett's-positive and Barrett's-negative groups based on histologic documentation of BE. The Kaplan-Meier and Cox regression analytic methods were used. We analyzed 362 patients with LEA (137 Barrett's-positive and 225 Barrett's-negative). A higher proportion of Barrett's-positive patients had (EUS)T2 cancers (27%) than those with Barrett's-negative cancer (17%). More Barrett's-negative LEAs involved gastroesophageal junction than Barrett's-positive ones (P = 0.001). The OS was significantly shorter for Barrett's-positive patients than that for Barrett's-negative patients (32 months vs. 51 months; P = 0.04). In a multivariate analysis for OS, Barrett's-positive LEA (P = 0.006), old age (P = 0.016), baseline positive nodes (P = 0.005), more than 2 positive (yp)N (P = 0.0001), higher (yp)T (P = 0.003), and the use of a taxane (0.04) were the independent prognosticators. Our data demonstrate that the clinical biology (reflected in OS) is less favorable for patients with Barrett's-positive LEA than for patients with Barrett's-negative LEA. Our intriguing findings need confirmation followed by in-depth molecular study to explain these differences.
Collapse
Affiliation(s)
- P Cen
- Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 2008; 22:127-32. [PMID: 19021681 DOI: 10.1111/j.1442-2050.2008.00884.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Activated nuclear factor-kappa B (NF-kappaB) in the pretreatment cancer tissue of patients with localized esophageal adenocarcinoma (LEA) undergoing preoperative chemoradiation is associated with poor prognosis. It is known that constitutively activated NF-kappaB prior to any therapy portends poor prognosis, and it is also known that activated NF-kappaB in the treated specimen is associated with poor prognosis. However, the prognosis of patients who have treatment-induced activation of NF-kappaB (meaning their cancers activate NF-kappaB during or after therapy) is not been reported. We hypothesized that the treatment-induced activation of NF-kappaB would impart poor prognosis similar to that imparted by constitutively activated NF-kappaB cancer. Patients with LEA who had undergone preoperative chemoradiation plus surgery and had pre- and post-therapy cancer tissue available were selected. Pre- and post-therapy cancer tissues were stained by immunohistochemistry for nuclear staining of NF-kappaB. The overall survival (OS) and disease-free survival were assessed and compared for patients who had intrinsic constitutively activated NF-kappaB cancer with those who had induced activation of NF-kappaB only post-therapy. A total of 41 patients with LEA were investigated. Twenty-five patients had NF-kappaB positive cancer at baseline, and 16 had NF-kappaB negative cancer at baseline but became positive post-therapy. There was no difference in the location, histology grade, clinical stage, or the curative resection (RO) resection rate in the two populations. OS (P = 0.71), disease-free survival (P = 0.86), and median survivals (Converters: 24 months [95% confidence intervals: 7.78 to 40.22]vs. Nonconverters: 34.13 months [95% confidence intervals: 3.54 to 64.27]) were not different between the two groups. Our data suggest that activation of NF-kappaB in response to stress/injury of therapy leads to poor OS. These results need to be confirmed in a larger number of patients. It may be that only pre-therapy evaluation of NF-kappaB is insufficient to assess prognosis of patients with LEA. Additional implications include that when effective anti-NF-kappaB therapies become available, they may have to be considered in patients whose cancers do not have constitutively activated NF-kappaB or cancer may have to be monitored during therapy with biomarker assessments.
Collapse
Affiliation(s)
- J G Izzo
- Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
|
33
|
Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15550] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Ho L, Phan AT, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani JA, Abbruzzese JL, Overman MJ. Retrospective review of docetaxel, cisplatin, and 5FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Cen P, Ajani JA, Correa AM, Lee JH, Maru DM, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA. Adenocarcinoma of the lower esophagus with Barrett’s or without Barrett’s: differences in patients survival after preoperative chemoradiation. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 2008; 21:575-81. [PMID: 18459989 DOI: 10.1111/j.1442-2050.2008.00829.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Thromboembolic event (TEE) is the most common complication and a second cause of mortality in cancer patients. Multiple hypotheses for occurrence of TEE have been proposed. There are no reports on the frequency/impact of TEE in localized gastroesophageal cancer patients. We hypothesized that TEE at baseline and during chemoradiotherapy (CTRT) in gastroesophageal cancer patients would have an impact on overall survival (OS) of these patients. All consecutive patients with gastroesophageal cancer undergoing CTRT from 2001 to 2004 were eligible for this analysis. Baseline and subsequent TEEs were documented and correlated with patient characteristics and OS. One hundred ninety-eight patients were analyzed. TEEs were documented in 9.6% of the patients. At baseline, TEEs were documented in 4.0% of the patients. During CTRT, TEEs were documented in 6.1% of the patients. Pulmonary embolism (43.5%) and lower extremity venous thromboses (39%) were the most frequent TEEs. Median OS for patients with a TEE occurring at anytime was 17.7 versus 32.0 months for patients who never developed a TEE (P = 0.014). TEEs at baseline correlated with poor median survival: 13.1 versus 30.7 months for those without a TEE (P = 0.029). In a multivariable analysis, TEE at baseline and/or during CTRT was an independent predictor of OS (hazard ratio, 1.818; P = 0.040). Our data are the first to document the frequency of TEE in gastroesophageal cancer patients undergoing CTRT, and that TEE is an independent prognosticator of OS. Active research to prevent and treat TEEs is needed to improve survival of patients with localized gastroesophageal cancer.
Collapse
Affiliation(s)
- E D Tetzlaff
- Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77005-4341, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TRJ. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 2008; 63:363-70. [DOI: 10.1007/s00280-008-0746-2] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2007] [Accepted: 03/17/2008] [Indexed: 10/22/2022]
|
38
|
Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs 2008; 12:227-32. [PMID: 18329956 DOI: 10.1016/j.ejon.2007.12.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2007] [Revised: 11/22/2007] [Accepted: 11/26/2007] [Indexed: 01/01/2023]
Abstract
Patients with advanced gastric cancer have a poor prognosis. Intensive chemotherapy regimens may be effective for the treatment of this disease but may be associated with a significant number of severe adverse events. Optimal management of these adverse events can improve outcome for the patient. Currently, there is little information in the literature about the nursing management of this particular group of patients. This American study involved the nursing management of all patients with gastric or gastroesophageal cancer enrolled in clinical trials at a single center. Patients had close contact with research nurses and received education about adverse events and how to deal with them. Patients completed a detailed treatment diary for each cycle of treatment. Protocols were established for the management of emergent adverse events. The guidelines developed during this study could help to underpin the role of the specialist oncology nurse and improve the management of patients undergoing intensive chemotherapy for gastric and gastroesophageal cancer, with the potential of improving outcome, or at least quality of life, for the patients. The nurses' role should be pivotal in the management of intensive chemotherapy for gastric and gastroesophageal cancer.
Collapse
Affiliation(s)
- J Baker
- Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.
| | | |
Collapse
|
39
|
Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4612] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4612 Background: Docetaxel combined with cisplatin/5-fluouracil resulted in significantly longer time-to-progression and survival but also 30% rate of complicated neutropenia (JCO 2006; 24:4991). To improve the safety profile of docetaxel-based therapy, we studied docetaxel with oxaliplatin/5-fluorouracil (D-FOX) to establish the first-cycle MTD (phase II trial to follow). Methods: Patients with histologic proof of gastric or gastroesophageal adenocarcinoma with untreated stage IV cancer were eligible. ECOG PS of <2, near-normal organ function, and written consent were other eligibility criteria. The initial doses of oxaliplatin (85mg/m2) and 5-fluorouracil (2.2g/m2 as 48-hour infusion), given every 2 weeks, were kept constant. Docetaxel was started at 20mg/m2 (Level 1) every 2 weeks in a typical 3x3 phase I design. Subsequent levels (+5mg/m2 every 4 weeks) were added. Fatigue, incompletely treated nausea, and oxaliplatin/5-flurouracil-related toxicities were excluded to determine the MTD. Results: A total of 36 patients have been treated. Currently, docetaxel dose is 47.5mg/m2 every 2 weeks (Level 11). MTD was not reached at Level 10. Overall, grade 3 or 4 first-cycle toxicities have occurred in <5% of patients and without complicated neutropenia. Fifteen of 34 patients have had a confirmed partial response, 13 had stability, and 6 patients had progression. Conclusions: The MTD of D-FOX has not yet been established but its safety profile (D-FOX with 45mg/m2 of docetaxel every 2 weeks) is excellent and the regimen is quite active against untreated gastric or gastoresophageal cancer. Translation studies and additional clinical data will be presented. Supported in part by sanofi-aventis pharma. [Table: see text]
Collapse
Affiliation(s)
| | - A. Phan
- MD Anderson Cancer Center, Houston, TX
| | - L. Ho
- MD Anderson Cancer Center, Houston, TX
| | | | - J. Baker
- MD Anderson Cancer Center, Houston, TX
| | - Q. Wei
- MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
40
|
Tetzlaff ED, Baker J, Ajani JA. Incidence of thromboembolic events (TEEs) before and during chemotherapy of patients with advanced gastric and gastroesophageal junction carcinoma (AG-GEJC) on clinical trials. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4073 Background: TEEs are associated with AG-GEJC and chemotherapy can further increase its incidence. We assessed TEEs before and during protocol chemotherapy for AG-GEJC patients. Methods: Patients with AG-GEJC on four approved protocols between August 1997 and September 2003 were assessed for baseline TEEs, new TEEs during therapy, histology, location of the primary, and overall survival. Three protocols evaluated camptothecin-based chemotherapy (irinotecan, peg-camptothecin, and rubitecan) and one evaluated non-camptothecin-based chemotherapy. Results: We studied 191 patients. Median age was 56 (range 20–80), Male:Female 151:40, chemotherapy naïve 132 (69%). 136 patients received irinotecan-based therapy and 55 patients received non-camptothecin-based therapy. Overall, TEEs occurred in 13.6% of patients. At baseline, TEEs were diagnosed in 5.3% of untreated patients and were diagnosed in 8.5% of patients with one prior chemotherapy regimen. During protocol therapy, TEEs occurred in 6.8% of untreated patients and 10.2% of previously treated patients. The most common TEE during protocol treatment was deep vein thrombosis (46.7%). First-line camptothecin-based chemotherapy was associated with TEEs in 6.5% of the patients. Non-camptothecin-based chemotherapy was associated with TEEs in 7.3% of the patients. Untreated patients receiving irinotecan plus cisplatin had the lowest incidence of TEEs (2.6%) during treatment. TEEs increased to 10.3% in second-line therapy with irinotecan plus cisplatin. Age, gender, location of the primary tumor, and histology did not differ between patients with or without a TEE during treatment. Survival data was available for 67 patients. The median survival of patients with a TEE at anytime was 3.7 months while it was 8.1 months for patients with no history of TEE. Conclusions: This is the first report describing TEEs at baseline and during chemotherapy for patients with AG-GEJC treated on chemotherapy protocols. The data show that chemotherapy is associated with higher risk of TEEs and TEEs influence survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - J. Baker
- M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
41
|
Perez RP, Lewis LD, Cohen GI, Hwang J, Malik S, Marshall JL, Baker J, Phan AT, Yao JC, Ajani JA. First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I):poly(C), in patients with liver metastases from various primary cancers. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13016 Background: NS-9 is a complex of poly-inosinate [poly(I)] and poly-cytidylate [poly(C)] in a cationic liposome and is active in vitro and in vivo. Objectives: to determine the tolerability, safety, and maximal tolerated dose (MTD), and pharmacokinetics of NS-9 by 1 hr IV infusion, given daily x5 q 28 days. Methods: A phase I dose escalation study was undertaken in patients with liver metastases from solid tumors. Eligible patients were adults with ECOG PS 0–1 and no recent chemotherapy (≥ 4 wks prior). Dose cohorts studied were 0.1, 0.15, 0.2, 0.3 and 0.4mg/m2. Results: 18 patients were enrolled (13M:5F) median age 58 (range 21 to 77 yrs). Tumor types included neuroendocrine (8), and ocular melanoma (1), gastric (1), GE junction (1), esophageal (2), and colorectal (5) carcinomas. Two of three patients treated at the first dose level (0.4 mg/m2) had grade 3/4 reversible lipase elevation with or without acute pancreatitis, a dose limiting toxicity (DLT). De-escalation to doses ranging from 0.1 to 0.2 mg/m2/day was with no DLT. At 0.3 mg/m2 two of three patients treated had a DLT (neutropenia and thrombocytopenia). The MTD was determined at 0.2 mg/m2. Common toxicities included pyrexia, chills, nausea, fatigue, abdominal pain, myalgia, anorexia, sweating, neutropenia, thrombocytopenia, and elevated glucose, amylase, and LFTs. Pharmacokinetics showed rapid elimination (T1/2 ranged from 2.4 to 5.0 hours) without accumulation after multiple doses. 1 patient (esophageal Ca) had a PR in the target lesions in the liver. Conclusions: The MTD is 0.2 mg/m2/day with a hint of antitumor activity. NS-9 should be pursued in phase-II studies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. P. Perez
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - L. D. Lewis
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - G. I. Cohen
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - J. Hwang
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - S. Malik
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - J. L. Marshall
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - J. Baker
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - A. T. Phan
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - J. C. Yao
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| | - J. A. Ajani
- Norris Cotton Cancer Center at Dartmouth, Lebanon, NH; Greater Baltimore Medical Center, Towson, MD; Georgetown University Hospital, Washington, DC; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
42
|
Izzo JG, Wu T, Malhotra U, Ensor J, Luthra R, Chao CK, Swisher SG, Liao Z, Aggarwal BB, Hittelman WN, Ajani JA. Transcription factor NFkB a potential molecular marker for predicting and improving treatment efficacy in esophageal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10065 Background: Esophageal/gastroesophageal junction adenocarcinoma (E/GEJAC) remains one of the most aggressive malignancies. Chemoradiotherapy (CTXRT) followed by surgery has been used for localized E/GEJAC. Patients (pts) achieving pathologic complete response (pathCR) have an improved survival, but ≈70% of pts exhibit at surgery resistant residual, highly aggressive tumors despite CTXRT. There is a need to identify this high-risk population and target molecular pathways associated with cancer resistance. We have shown that nuclear NFκB was associated with poor clinical outcome of E/GEJAC pts undergoing 5FU, Docetaxel and Cisplatinum therapy. To validate our findings, we examined the impact of nuclear NFκB on clinical outcome of pts undergoing diverse CTXRT regimens. Methods: Pre- treatment tumor biopsies and post-treatment resected residual tumors were analyzed from pts receiving neo-adjuvant CT or CTXRT. NFκB protein expression was assessed by immunochemistry and correlated to pathCR and clinical outcome. Tumors were considered NFκB positive (pos) when ≥5% of cells expressed nuclear NFκB. Results: 80 pts, clinically staged II, III and IVA, were studied. All pts received antifolates, and 80%, 65% & 31% received taxanes, topo-1 inhibitors and/or platinum analogues, respectively. Radiation therapy was 50.4 Gy at 1.8 Gy once a day to all pts. 75/80 pts had available pre-treatment biopsies, all 58 pts with <pathCR had available residual tumors. Pre-treatment NFκB was predictive for lack of response to CTXRT [NFκB pos: 2/22 pathCR vs 27/53 <pathCR; P=.006]. In multivariate analysis, including clinical stage, tumor histology, pathCR and lymph nodes metastasis, pre-treatment NFκB was an independent prognostic factor of progression-free (P=.0029, HR=2.90, 95%CI:1.44–5.86) and overall (P=.0073,HR=2.70, 95%CI:1.30–5.60) survivals. NFκB was associated with recurrent disease [pre-treatment NFκB pos 14/29 (48%) vs NFκB negative11/46 (24%), P=.04; pre- or post- NFκB pos 22/47 (47%) vs NFκB neg 4/33 (12%), P=.003]. Conclusions: our data suggest that NFκB defines cancer biology and patterns to therapy response irrespective of the type of chemoradiation used. NFκB may serve as potential molecular target to improve treatment efficacy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. G. Izzo
- UT M. D. Anderson Cancer Center, Houston, TX
| | - T. Wu
- UT M. D. Anderson Cancer Center, Houston, TX
| | - U. Malhotra
- UT M. D. Anderson Cancer Center, Houston, TX
| | - J. Ensor
- UT M. D. Anderson Cancer Center, Houston, TX
| | - R. Luthra
- UT M. D. Anderson Cancer Center, Houston, TX
| | - C. K. Chao
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | - Z. Liao
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | | | - J. A. Ajani
- UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
43
|
Lenz H, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara RH, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4083 Background: We obtained additional phase II safety and efficacy data in a multi-center setting on an active regimen of S-1 plus cisplatin; the experimental arm of the global phase III First-Line Advanced Gastric cancer Study (FLAGS). Methods: Eligible patients had untreated advanced gastric cancer (AGC), histologic proof, KPS ≥70%, adequate organ function, and gave written consent. Patients received S-1 (25mg/m2 p.o. bid on days 1–21) plus cisplatin (75mg/m2 i.v. on day 1) every 28 days. All reported confirmed overall response rate (C-ORR), response durations, and time-to-progression (TTP) are externally reviewed. Results: All 72 patients were assessed for safety and 64 for efficacy. The median age was 56 years and median KPS was 90%. Median no. of cycles was 4. C-ORR was 50% (95% CI, 37%-63%). Median duration of response is >6 months. At 6 months, only 35% of patients have had cancer progression. Median survival (n=72) is 10.5 months (95% CI, 9.3 to NR). At least one SAE occurred in 43% of patients. The frequent grade 3 or 4 adverse events (occurring in >10% of patients) included: fatigue/asthenia (26%), vomiting (21%), nausea (18%), diarrhea (17%), neutropenia (18%), anorexia (11%), and dehydration (11%). Febrile neutropenia (1.4%) and grade 4 diarrhea (1.4%) were rare. Conclusions: These extended data confirm that S-1 plus cisplatin has a very desirable safety profile and impressive efficacy data in AGC. FLAGS will complete accrual of >700 patients by March of 2007. (Supported by Taiho Pharma-USA). [Table: see text]
Collapse
Affiliation(s)
- H. Lenz
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - F. C. Lee
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - D. G. Haller
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - D. Singh
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - A. B. Benson
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - D. Strumberg
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - R. H. Yanagihara
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - J. C. Yao
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - A. T. Phan
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| | - J. A. Ajani
- USC Norris Comprehensive Cancer Center, Los Angeles, CA; University of New Mexico, Albuquerque, NM; University of Pennsylvania Cancer Center, Philadelphia, PA; University of Chicago, Chicago, IL; Northwestern University, Chicago, IL; University of Essen, Essen, Germany; St Louise Hospital, Gilroy, CA; M.D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
44
|
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas C, Mayer RJ, Haddock MG, Willett C, Willett C, Rich TA. Intergroup RTOG 98–11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4009] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4009 Background: An ∼65% 5-year disease-free-survival (DFS) rate from 5-FU/mitomycin/radiation for anal carcinoma needs improvement. Methods: A phase III randomized trial compared 5-FU (1,000mg/m2 days 1–4 and 29–32) plus mitomycin (10mg/m2 days 1 and 29) and radiation (45 to 59 Gy) (Arm A) to 5-FU (1,000mg/m2 days 1–4, 29–32, 57–60 and 85–88) plus cisplatin (75mg/m2 on days 1, 29, 57 and 85) and radiation (45 to 59 Gy; start day=57) (Arm B) in anal carcinoma patients. Stratification included gender, clinical N status and tumor diameter. Primary endpoint was DFS. Statistical power was 80% with two-sided test to detect 10% DFS increase for Arm B. Results: Of 682 patients accrued, 598 were analyzable. Most unanalyzed patients’ data are early. Patient characteristics were balanced. Median age was 55 years, women predominated (69%), 27.5% had >5 cm tumor diameter and 26% had clinically N+ cancer. Preliminary 5-year estimated DFS was 56% for Arm A and 48% for Arm B (p=0.28) and 5-year estimated overall survival was 69% for both arms (p=0.24). Men(p=0.04), clinically N+ cancer (p<0.0001) and tumor diameter >5 cm (p=0.005) independently prognosticated DFS in a multivariate analysis. 5-year colostomy rate was 10% for Arm A and 20% for arm B(p=0.12). Grade 3/4 toxicity rates: non-hematologic=76% for Arm A and 75% for Arm B but hematologic=67% for Arm A and 47% for Arm B(p=0.0004). Conclusions: In Intergroup-98–11, induction 5-FU/cisplatin followed by 5-FU/cisplatin/radiation failed to improve DFS compared to the standard treatment, 5-FU/mitomycin/radiation. Supported by RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Ajani
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - K. A. Winter
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - L. L. Gunderson
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - J. Pedersen
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - A. B. Benson
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - C. Thomas
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - R. J. Mayer
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - M. G. Haddock
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - C. Willett
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - C. Willett
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| | - T. A. Rich
- M. D. Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Alberta, Edmonton, AB, Canada; Northwestern University, Chicago, IL; OHSU, Portland, OR; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Duke University Medical Center, Durham, NC; University of Virginia Medical Center, Charlottesville, VA
| |
Collapse
|
45
|
Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus 2006; 19:152-7. [PMID: 16722991 DOI: 10.1111/j.1442-2050.2006.00557.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The purpose of this study was to identify gender-dependent differences in presentation at baseline and therapy outcome in esophageal carcinoma patients treated with preoperative chemoradiotherapy (CTRT). We stratified patients according to gender and statistically compared pretreatment clinical stage, post-CTRT effect on carcinoma in the resected specimen, overall survival (OS), and patterns of failure. Of the 235 patients who underwent preoperative CTRT, 203 were men and 32 were women. Carcinomas in women correlated significantly with clinical stage II classification (78%vs. 55%) while cancers in men correlated significantly with clinical stage III classification (39%vs. 16%; P = 0.02). Carcinomas in women also correlated significantly with lower clinical N classification; more women had cN0 (52%) compared to men (28%; P = 0.01). Similarly, in the surgical specimens, more women had pN0 (78%) compared to men (64%; P = 0.06). At a median follow-up of 37 months, 10% more women than men remain alive (63%vs. 53%; P = 0.3). Distant metastases-free survival time was longer for women than men. Our results suggest that localized esophageal carcinoma is diagnosed in more advanced stages in men than in women. The reasons for these differences remain unclear and further expansion of these observations and study of biologic differences that might exist are warranted.
Collapse
Affiliation(s)
- P R Rohatgi
- Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006; 24:441-6. [PMID: 16586011 DOI: 10.1007/s10637-006-7304-8] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
PURPOSE Ixabepilone is one of the epothilones, a new class of cytotoxics, that function as microtubule-stabilizing agents. With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial. PATIENTS AND METHODS Patients with histologically documented metastatic gastric or gastroesophageal adenocarcinoma, who had previously received a taxane, were eligible. Patients were required to have near normal organ function, > or =18 years of age, ECOG performance status of 0 or 1. A written informed consent was obtained from all patients. Ixabepilone was administered over one hour intravenously at a dose of 50 mg/m2 every 21 days (23 patients; cohort A) and 24 subsequent patients were treated with an amended protocol schedule to receive 6 mg/m2 intravenously on days 1-5 every 21 days (cohort B). RESULTS A total of 47 patients were treated. Most patients were men with a median performance status of 1. Two of 23 patients in cohort A achieved a confirmed partial response (9%, 95% CI 1.1-28%) but none of the 24 patients in cohort B achieved a response. A higher proportion of patients in cohort A experienced Grade 3/4 toxicities compared with those in cohort B. CONCLUSIONS Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinoma patients.
Collapse
Affiliation(s)
- J A Ajani
- The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas, 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ajani JA, Phan A, Yao JC, Lee FC, Singh DA, Haller D, Benson AB, Lenz HJ, Yanagihara RH, Strumberg D. Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. A. Ajani
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - A. Phan
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - J. C. Yao
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - F.-C. Lee
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - D. A. Singh
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - D. Haller
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - A. B. Benson
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - H.-J. Lenz
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - R. H. Yanagihara
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| | - D. Strumberg
- MD Anderson Cancer Ctr, Houston, TX; UNM Cancer Research and Treatment Ctr, Albuquerque, NM; The Univ of Chicago, Chicago, IL; Univ of Pennsylvania Medcl Ctr, Philadelphia, PA; Northwestern Univ, Chicago, IL; USC/Norris Comprehensive Cancer Ctr, Los Angeles, CA; St. Louise Regional Hosp, Gilroy, CA; Univ Medcl Sch of Bochum, Herne, Germany
| |
Collapse
|
48
|
Okawara GS, Winter K, Donohue JH, Pisters PWT, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willet C, Ajani JA. A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach (RTOG 99–04). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. S. Okawara
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - K. Winter
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. H. Donohue
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - P. W. T. Pisters
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - C. H. Crane
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. F. Greskovich
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - P. R. Anne
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. D. Bradley
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - C. Willet
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| | - J. A. Ajani
- McMaster Univ, Hamilton, ON, Canada; Radiation Therapy Oncology Group Headquarters, Philadelphia, PA; Mayo Clinic, Rochester, MN; M.D. Anderson Cancer Ctr, Houston, TX; Univ Hospitals, Cleveland, OH; Thomas Jefferson Univ Hosp, Philadelphia, PA; Washington Univ Sch of Medicine, St Louis, MO; Duke Univ Medcl Ctr, Durham, NC
| |
Collapse
|
49
|
Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter W, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. Number of lymph nodes with metastasis predict survival in patients with esophageal or esophagogastric junction adenocarcinoma treated with preoperative chemoradiation. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Gu
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | | | | | | | - Z. Liao
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | - A. Rashid
- UT M. D. Anderson Cancer Ctr, Houston, TX
| | | | - T.-T. Wu
- UT M. D. Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
50
|
Yao JC, Ng C, Hoff PM, Phan AT, Hess K, Chen H, Wang X, Abbruzzese JL, Ajani JA. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4007] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. C. Yao
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - C. Ng
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - P. M. Hoff
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - A. T. Phan
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - K. Hess
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - H. Chen
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - X. Wang
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - J. L. Abbruzzese
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| | - J. A. Ajani
- UT M. D. Anderson Cancer Ctr, Houston, TX; National Cancer Institute, Bethesda, MD
| |
Collapse
|